{"id":"NCT01068600","sponsor":"Novartis","briefTitle":"Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks","officialTitle":"A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2010-06","completion":null,"firstPosted":"2010-02-15","resultsPosted":"2011-08-19","lastUpdate":"2011-08-19"},"enrollment":318,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Indacaterol","otherNames":[]},{"type":"DRUG","name":"Placebo to indacaterol","otherNames":[]}],"arms":[{"label":"Indacaterol 75 µg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment","timeFrame":"after 12 weeks","effectByArm":[{"arm":"Indacaterol 75 µg","deltaMin":1.49,"sd":0.016},{"arm":"Placebo","deltaMin":1.35,"sd":0.015}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":54,"countries":["United States"]},"refs":{"pmids":["23020650","22177371"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":159},"commonTop":["Chronic obstructive pulmonary disease","Cough","Nasopharyngitis","Upper respiratory tract infection","Oropharyngeal pain"]}}